Dual tetravalent CD40 costimulator/anti-FAP ( Jiangsu Hengrui Pharmaceuticals/Shanghai Suncadia Medicine)

N/A

Report date: 2025/05/15 16:39:20

Base Information

Drug NameDual tetravalent CD40 costimulator/anti-FAP ( Jiangsu Hengrui Pharmaceuticals/Shanghai Suncadia Medicine)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionAnti-Prolyl endopeptidase FAPTumor necrosis factor receptor superfamily member 5 modulators
TargetsProlyl endopeptidase FAPTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Hengrui Pharmaceutical Group Co LtdShanghai Suncadia Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Suncadia Medicine Co LtdJiangsu Hengrui Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A